VAFP
NVAX icon

Vahanian & Associates Financial Planning’s Novavax NVAX Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,915
Closed -$215K – 55
2022
Q1 		$215K Sell
2,915
-1,522
-34% -$136K 0.5% 54
2021
Q4 		$635K Buy
+4,437
New +$762K 0.51% 50

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vahanian & Associates Financial Planning's NVAX Position: Q2 2022 in Review

Vahanian & Associates Financial Planning sold out of Novavax (NVAX) in Q2 2022, closing a stake of 2,915 shares — an estimated $215K sold.

Vahanian & Associates Financial Planning first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $635K in Q4 2021. 326 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

  • Vahanian & Associates Financial Planning reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
  • Vahanian & Associates Financial Planning sold 2,915 Novavax shares in Q2 2022, an estimated $215K.
  • Vahanian & Associates Financial Planning first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
  • Vahanian & Associates Financial Planning's Novavax position peaked at $635K in Q4 2021.
  • 326 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Vahanian & Associates Financial Planning's 13F filing for Q2 2022, filed 27 Jul 2022.